Ghrelin Receptor Agonists - Pipeline Insight, 2025

This “Ghrelin Receptor Agonist - Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ghrelin Receptor Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Ghrelin Receptor Agonist Understanding

Ghrelin Receptor Agonist: Overview

Ghrelin is a hormone produced by specific cells in the stomach. It exerts its action by binding to receptors in the hypothalamus involved in the regulation of food intake. Ghrelin causes an increase in the pituitary secretion of growth hormone (GH). Drugs that bind and activate the ghrelin receptor have been explored for their effect on appetite, weight gain, frailty, cachexia, inflammation and gut motility. Ghrelin exerts its effects through a specific G‐protein‐coupled receptor called the growth hormone secretagogue receptor 1a (GHS‐R1a). Another GHS‐R cDNA is produced by alternative splicing which produces a COOH‐terminal truncated form (GHS‐R1b) that is pharmacologically inactive. The GHS‐R1a is expressed in several areas of the hypothalamus associated with feeding behaviour, including the arcuate and ventromedial nuclei. GHS‐R1a is also found in the pituitary gland, and other organs such as bone, heart, lung, liver, kidney, pancreas and immune cells.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ghrelin Receptor Agonist R&D. The therapies under development are focused on novel approaches for Ghrelin Receptor Agonist.

Ghrelin Receptor Agonist Emerging Drugs Chapters

This segment of the Ghrelin Receptor Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ghrelin Receptor Agonist Emerging Drugs

Anamorelin HCl: Helsinn Therapeutics/Ono Pharmaceutical

Anamorelin HCl is an orally-active selective ghrelin receptor agonist which has shown anabolic and appetite-stimulating effects. everal randomized, double-blind, clinical trials in cancer patients have shown that anamorelin HCL is safe, efficacious and increases lean body mass, bodyweight, and appetite. Investigators propose to test anamorelin HCL administered with chemotherapy in the first-line treatment of locally advanced unresectable and metastatic pancreatic cancer. Its Phase II trial is expected to start in August 2021.

Ghrelin Receptor Agonist: Therapeutic Assessment

This segment of the report provides insights about the different Ghrelin Receptor Agonist drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Ghrelin Receptor Agonist

There are approx. 5+ key companies which are developing the Ghrelin Receptor Agonist. The companies which have their Ghrelin Receptor Agonist drug candidates in the most advanced stage, i.e. Phase II include, Helsinn Therapeutics/Ono Pharmaceutical.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ghrelin Receptor Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ghrelin Receptor Agonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ghrelin Receptor Agonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ghrelin Receptor Agonist drugs.

Ghrelin Receptor Agonist Report Insights

• Ghrelin Receptor Agonist Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ghrelin Receptor Agonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Ghrelin Receptor Agonist drugs?
• How many Ghrelin Receptor Agonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Ghrelin Receptor Agonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ghrelin Receptor Agonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ghrelin Receptor Agonist and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Helsinn Therapeutics/Ono Pharmaceutical
• AEterna Zentaris

Key Products

• Anamorelin HCl
• Macimorelin

This product will be delivered within 2 business days.